CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

摘要: Rationale and Objectives Determine inter- intraobserver variability of computed tomography (CT) tumor volume measurements in advanced non-small-cell lung cancer (NSCLC) patients treated a Phase II clinical trial using chest CT. Materials Methods Twenty-three NSCLC with total 53 measurable lesions enrolled II, multicenter, open-label erlotinib were retrospectively studied institutional review board approval. Two radiologists independently measured the size, volume, CT attenuation coefficient commercially available analysis software. Concordance correlation coefficients (CCCs) Bland-Altman plots used to assess agreement. Results High CCCs (0.949–0.990) observed all types for interobserver The 95% limits agreements unidimensional, bidimensional (−26.0%, 18.6%), (−23.1%, 24.4%), (−34.0%, 48.6%), respectively. Volume measurement had slightly higher CCC narrower agreement compared uni- measurements. high (range, 0.946–0.996) being than smaller was, larger difference attenuation. Location, morphology, or adjacent atelectasis no significant impact on variability. Conclusion software demonstrated agreement, indicating that method may be routinely practice.